UroGen Pharma (URGN) Q3 2024 earnings summary

Executive summary

• FDA accepted the NDA for UGN-102, with a PDUFA target date of June 13, 2025, marking a major regulatory milestone and potential commercial launch in 2025 for a novel therapy in low-grade, intermediate-risk, non-muscle-invasive bladder cancer.

• UGN-102 targets a significantly larger market than Jelmyto, with over 80,000 addressable patients annually in the U.S. and a total addressable market exceeding $5 billion.

• Jelmyto net product revenue reached $25.2 million in Q3 2024, up from $20.9 million in Q3 2023, driven by strong patient demand and increased prescriber engagement.

• Cash, cash equivalents, and marketable securities totaled $254.2 million as of September 30, 2024, providing runway beyond one year and supporting upcoming launches.

• The company is preparing for a robust commercial launch of UGN-102, including doubling its sales force and expanding pre-commercial activities.

Financial highlights

• Q3 2024 Jelmyto net product revenue was $25.2 million, compared to $20.9 million in Q3 2023.

• Net loss for Q3 2024 was $23.7 million ($0.55 per share), compared to $21.9 million ($0.68 per share) in Q3 2023.

• R&D expenses rose to $11.4 million in Q3 2024, mainly due to the initiation of the phase III UTOPIA trial for UGN-103.

• SG&A expenses increased to $28.9 million in Q3 2024, driven by UGN-102 pre-commercialization activities.

• Gross profit for Q3 2024 was $22.8 million, up from $18.5 million in Q3 2023.

Outlook and guidance

• Full-year Jelmyto revenues are expected to deliver low double-digit growth, though below the low end of previous guidance due to gross-to-net headwinds.

• 2024 operating expenses are projected near the midpoint of $175–$185 million, including $9–$13 million in non-cash share-based compensation.

• Non-cash financing expense for 2024 is expected to be $21–$26 million.

• Management believes current cash reserves are sufficient to reach profitability and support the UGN-102 launch.

• Expectation of continued operating losses and negative cash flows as R&D and commercialization efforts expand.